Triple-negative breast cancer (TNBC) constitutes a small subtype (~15%) of breast cancer, but causes the majority of breast cancer-related deaths.

The research described in this thesis focused on identifying novel drug targets and synergistic combinations for triple-negative breast cancer (TNBC), a virulent subtype of breast cancer with a dismal prognosis and limited therapeutic options.

The work of judges can also be done by AI systems. These systems can formulate an objective proposal for a ruling. But such proposal should always be checked by a judge, says Bart Custers.

Promotor: A.H. Meijer, Co-promotor: B.E. Snaar-Jagalska

Lecture

In this thesis, we used genetically engineered mouse models and a variety of cell-culture based assays to identify genes and pathways that are involved in the development and treatment of invasive lobular carcinoma (ILC).

In this thesis, we used genetically engineered mouse models to identify genes and pathways that are involved in ILC formation and in the development of resistance to FGFR-targeted therapy.

Promotor: E. Bouwman, Co-promotor: S. Bonnet

What are the biological effects of Chinese herbal medicine in regulation of cancer cell metastasis?

The potential of liposomal cancer vaccines

G protein-coupled receptors (GPCRs), one of the largest families of membrane proteins, are responsive to a diverse set of physiological endogenous ligands including hormones and neurotransmitters.

Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.

Promotores: W. Jiskoot, F. Ossendorp

Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.

Prostate cancer (PCa) is one of the most prevalent cancer in males.

This thesis focuses on using liposomes in two different treatment strategies; vaccination (or immunotherapy) and delivery of a small molecule, and in two different disease models; cancer and atherosclerosis.

Winning a prestigious award for PhD researchers, even before you have your doctorate: that's what Yascha van den Berg managed to do with his research proposal on alternatively spliced tissue factor, a protein that may be involved in tumour growth. Van den Berg: ‘It all started as a Friday afternoon…

PhD student Esmee Koedoot studied the underlying processes responsible for metastases in a dangerous type of breast cancer. She hopes to find new possibilities to fight the disease. In December 2019 she obtained her doctorate cum laude.

Zebrafish-human communication shows that cancer cells lacking a signaling protein are less able to develop aggressive metastatic properties. This discovery has been made by molecular cell biologist Claudia Tulotta. PhD defence 14 June.

We already know a lot about genetics and the risk of breast cancer. But much still needs to be done in breast cancer genetics to improve the prognosis and make sure women at high risk aren’t missed. This is what Professor by Special Appointment Marjanka Schmidt will say in her inaugural lecture on 4…

Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…

The immune system plays a paradoxical role in the spread of breast cancer. Some immune cells contribute to metastasis, while other cells can be activated to strengthen the effect of chemotherapy. Kelly Kersten made this discovery in her PhD research. PhD defence 7 February.

Leiden biophysicist Stefano Coppola has received the prestigious AXA Research Fund postdoctoral fellowship. With this grant he can work for two years on a project to research the role of mechanical factors in the development of pancreatic cancer.

Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…

Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…

Ewa Snaar-Jagalska, Shuning He and colleagues from IBL, LION and LACDR reported on a new zebrafish study to understand micrometastasis of human cancer cells. They discovered a novel role for neutrophils in assisting metastasis formation, which provides critical insights for anti-cancer therapies.

As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.

Leiden University Medical Center (LUMC) has spent the past five years coordinating an international study of genetic mutations and breast cancer risks. The results will make it easier to determine which genes increase the risk of breast cancer and to what extent. The researchers published their results…

PhD defence

Ariane Briegel wants to use bacteria to detect cancer at an early stage. Together with postdoc Alise Muok, she is developing a method to quickly and cheaply test the urine of patients for the presence of suspicious molecules. They receive a grant of approximately 150,000 euros from the Dutch Cancer…

Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer.

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

To inhibit proteins that contribute to the growth of aggressive cancer cells, that’s the plan of Professor Bob van de Water and his team. They will receive over 700,000 euros from the KWF Dutch Cancer Society for their research. Researcher Maaike Vreeswijk and pathologist Danielle Cohen are affiliated…

With a Vici grant of 1.5 million euros, Professor of Mathematical biology Roeland Merks will look for ways to fix messy and leaky blood vessels in tumours. His research combines mathematical simulations and lab experiments in a unique way.

Modified viruses can both kill cancer cells and activate the immune system. This is what an LUMC team discovered while researching a new prostate cancer therapy.

A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by ISA Pharmaceuticals B.V. (a Leiden-based biotechnology company) and the Leiden University Medical Center (LUMC) shows that this vaccine produces a more robust response…

Chemist Gerjan de Bruin has designed a method of slowing down the degradation process of proteins in cells. This may contribute to new cancer medicines with fewer side-effects. PhD defence on 1 June.

In breast cancer, metastasis rather than the primary tumour is the cause of death. A lack of oxygen in the tumour cells promotes this metastasis, accompanied by a reprogramming of the cell's metabolism. PhD candidate Qiuyu Liu investigated these alterations to get more knowledge about the actionable…

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

Cell biologist Erik Danen has been awarderd a grant of half a million euros to study how tumor cells spread throughout the body en develop drug resistance. This was announced mid-August by the Dutch Cancer Society Fund (KWF).

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.

Researchers at Leiden University have mapped genes that cause breast cancer cells to migrate. The Leiden toxicologists Professor Bob van de Water, Dr Wies van Roosmalen, Dr Sylvia E. Le Dévédec and colleagues studied 1500 individual genes. They found eight, including the SRPK1 gene, that regulate the…

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

The European Commission has granted budget for the project INFORM (Introduction of the data protection reform to the judicial system). Dr. Bart Custers, associate professor and head of research at eLaw, the Center for Law and Digital Technologies, has written the proposal with nine partner organizations…

This year’s theme of the Cyber Summit is: “Using Technology Responsible”. The Cyber Summit will take place in Banff, Canada on October 26th-28th. Dr. Bart Custers, associate professor and head of research at eLaw, the Center for Law and Digital Technologies, is invited to give a presentation on privacy…

The European Commission has granted budget for the project e-SIDES (ethical and societal implications of data science). Dr. Bart Custers, associate professor and head of research at eLaw, the Center for Law and Digital Technologies, has written the proposal with two partner organizations within the…

Leiden researchers have developed a groundbreaking model to advance cancer immunotherapy. Using a 3D printer, they create mini-tumors within an environment that closely mimics human tissue. They have also developed a method to monitor real-time interactions of these mini-tumours with immune cells during…